aibioVor Bio licenses telitacicept from RemeGen for $45 million plus $80 million in warrants
Tickers VOR
Vor Bio agreed to pay RemeGen a $45 million upfront payment and $80 million in warrants for global rights to telitacicept, excluding Greater China. The only efficacy result cited is from a China Phase 3 study, and initial global results are expected in the first half of 2027.
Key facts
- Company
- Vor Biopharma Inc. (NASDAQ: VOR)
- News type
- Financings
- Primary source
- Vor Biopharma Inc. 8-K (2025-06-26)
Vor Bio, Inc., a clinical-stage biotechnology company in Cambridge, Massachusetts, listed on Nasdaq as VOR, and RemeGen Co., Ltd., a Chinese biopharmaceutical company listed in Hong Kong and Shanghai, announced on June 25, 2025 an exclusive license agreement. Vor Bio receives global rights to develop and commercialize telitacicept, excluding China, Hong Kong, Macau and Taiwan. The release was filed with the SEC as Exhibit 99.1 on June 26, 2025.
Telitacicept is a fusion protein that targets BLyS, also called BAFF, and APRIL, two cytokines the companies describe as critical to B cell survival. It is approved in China for generalized myasthenia gravis, systemic lupus erythematosus and rheumatoid arthritis.
The payments
Vor Bio will pay RemeGen an initial $125 million. That is made up of a $45 million upfront payment and $80 million of warrants to buy Vor Bio common stock at an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, plus tiered royalties.
The warrants are the larger part of the initial payment. Because they carry a nominal exercise price, RemeGen would hold a stake in Vor Bio once they are exercised. The release does not say how many shares the warrants cover, what percentage of Vor Bio they would represent, or when they could be exercised. Those terms would decide how much existing holders are diluted, and the release does not give them.
The trial record
The only efficacy result in the release comes from China. In a Phase 3 trial of telitacicept in generalized myasthenia gravis, the drug showed a 4.8-point improvement on the MG-ADL scale against placebo at 24 weeks, which the company describes as the primary endpoint. The release does not give the number of patients in that study.
The global Phase 3 trial in generalized myasthenia gravis is run by RemeGen. It is enrolling in the United States, Europe and South America, with initial results expected in the first half of 2027. Vor Bio is therefore paying for a drug whose global efficacy data do not exist yet. The release's own list of risks includes whether interim results will predict final results, whether regulators will allow the trials to proceed, and whether there will be enough funding for operating expenses. It also names Vor Bio's ability to continue as a going concern.
Leadership change
The same day, Vor Bio's board appointed Jean-Paul Kress, M.D., as chief executive officer and chairman. Robert Ang resigned from both roles and will stay on as a strategic advisor through October 2025. The release says Kress most recently served as chief executive of MorphoSys, where he led the approval of Monjuvi, tafasitamab, and the 2021 acquisition of Constellation Pharmaceuticals. It says MorphoSys was acquired by Novartis in 2024. He also sits on the board of Sanofi S.A. Before MorphoSys he was chief executive of Syntimmune, whose lead immunology program was acquired by Alexion Pharmaceuticals. Kress said in the release that targeting BAFF/APRIL signaling represents "a significant advancement in addressing autoantibody driven diseases." Jianmin Fang, RemeGen's chief executive, said the out-licensing of ex-China rights accelerates the company's mission to deliver the therapy to patients worldwide. RemeGen, founded in 2008, describes its focus as autoimmune, oncology and ophthalmic diseases.
What the release leaves out
The release names no bank, placement agent, financial advisor or counsel for the transaction. It gives no cash balance, no net loss and no runway for Vor Bio, and it does not say how the $45 million upfront payment will be funded.
The company's most recent annual report, the 10-K for 2024 filed on March 20, 2025, lists among its forward-looking topics the period over which existing cash, cash equivalents and marketable securities will fund operations. The release does not update that period for the deal.
The release describes Vor Bio as a clinical-stage company focused on advancing telitacicept through Phase 3 development. The only efficacy result it cites comes from a trial in China, and the warrant position for RemeGen has no stated size.